{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:57:55Z","timestamp":1787500675327,"version":"build-2736575974"},"reference-count":26,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The purpose of this study was to analyze medical late effects among patients with chronic myeloid leukemia (CML) treated with hematopoietic cell transplantation (HCT). Subjects included 248 CML survivors who received an HC transplant (related donors [RDs], n = 150; unrelated donors [URDs], n = 70; or autologous, n = 28) and had survived at least 2 years, and a comparison group of 317 siblings. Subjects completed a 238-item survey on medical late effects. Compared with siblings, survivors were at a higher risk of developing ocular, oral health, endocrine, gastrointestinal, musculoskeletal, neurosensory, and neuromotor impairments. Multivariate analysis limited to RD and URD recipients found that chronic graft-versus-host disease (cGVHD) was associated with a higher risk of hypothyroidism, osteoporosis, cardiopulmonary, neurosensory, and neuromotor impairments. Overall health was reported as excellent, very good, or good in 78% of subjects, although those with cGVHD were more likely to report poor overall health. URD survivors were more likely to report a need for assistance with routine activities and that their current health prevented work or school attendance. This study demonstrates that HCT survivors, regardless of donor type, have a high prevalence of long-term health-related complications. However, adverse medical late effects with significant morbidity were uncommon. Chronic GVHD is the most important predictor of adverse medical late effects and poor overall health.<\/jats:p>","DOI":"10.1182\/blood-2004-03-1010","type":"journal-article","created":{"date-parts":[[2004,6,7]],"date-time":"2004-06-07T20:18:21Z","timestamp":1086639501000},"page":"1898-1906","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":121,"title":["Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study"],"prefix":"10.1182","volume":"104","author":[{"given":"K. Scott","family":"Baker","sequence":"first","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Gurney","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten K.","family":"Ness","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liton","family":"Francisco","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip B.","family":"McGlave","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie L.","family":"Robison","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Snyder","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Bhatia","sequence":"additional","affiliation":[{"name":"From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology\/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223564657700_REF1","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003;98: 437-457.","DOI":"10.1002\/cncr.11520"},{"key":"2020021223564657700_REF2","doi-asserted-by":"crossref","unstructured":"Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood. 2003;102: 31-35.","DOI":"10.1182\/blood-2002-08-2619"},{"key":"2020021223564657700_REF3","doi-asserted-by":"crossref","unstructured":"Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol. 2003; 40: 59-71.","DOI":"10.1016\/S0037-1963(03)70043-2"},{"key":"2020021223564657700_REF4","doi-asserted-by":"crossref","unstructured":"Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med. 2001;110: 339-346.","DOI":"10.1016\/S0002-9343(01)00629-5"},{"key":"2020021223564657700_REF5","doi-asserted-by":"crossref","unstructured":"Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104: 155-163.","DOI":"10.7326\/0003-4819-104-2-155"},{"key":"2020021223564657700_REF6","doi-asserted-by":"crossref","unstructured":"Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of un-related versus matched sibling donor transplantation. Blood. 2002;99: 1971-1977.","DOI":"10.1182\/blood.V99.6.1971"},{"key":"2020021223564657700_REF7","doi-asserted-by":"crossref","unstructured":"Snyder DS, Negrin RS, O'Donnell MR, et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood. 1994;84: 1672-1679.","DOI":"10.1182\/blood.V84.5.1672.1672"},{"key":"2020021223564657700_REF8","doi-asserted-by":"crossref","unstructured":"Goldman JM, Szydlo R, Horowitz MM, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82: 2235-2238.","DOI":"10.1182\/blood.V82.7.2235.2235"},{"key":"2020021223564657700_REF9","unstructured":"Enright H, Daniels K, Arthur DC, et al. Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Bone Marrow Transplant. 1996;17: 537-542."},{"key":"2020021223564657700_REF10","doi-asserted-by":"crossref","unstructured":"van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood. 1994;83: 3377-3383.","DOI":"10.1182\/blood.V83.11.3377.3377"},{"key":"2020021223564657700_REF11","doi-asserted-by":"crossref","unstructured":"Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol. 2002;20: 2334-2343.","DOI":"10.1200\/JCO.2002.06.077"},{"key":"2020021223564657700_REF12","doi-asserted-by":"crossref","unstructured":"Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001; 98: 3569-3574.","DOI":"10.1182\/blood.V98.13.3569"},{"key":"2020021223564657700_REF13","doi-asserted-by":"crossref","unstructured":"Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002; 38: 229-239.","DOI":"10.1002\/mpo.1316"},{"key":"2020021223564657700_REF14","doi-asserted-by":"crossref","unstructured":"Louie AD, Robison LL, Bogue M, Hyde S, Forman SJ, Bhatia S. Validation of self-reported complications by bone marrow transplantation survivors. Bone Marrow Transplant. 2000;25: 1191-1196.","DOI":"10.1038\/sj.bmt.1702419"},{"key":"2020021223564657700_REF15","unstructured":"Anderson WN. Actuarial and actual analysis. Proceedings of the 8th Annual Western Users of SAS Software (WUSS). http:\/\/lib.sta.cmu.edu\/general\/Markov.sas. Accessed July 12, 2004."},{"key":"2020021223564657700_REF16","unstructured":"Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons; 1981."},{"key":"2020021223564657700_REF17","doi-asserted-by":"crossref","unstructured":"Baker F, Curbow B, Wingard JR. Role retention and quality of life of bone marrow transplant survivors. Soc Sci Med. 1991;32: 697-704.","DOI":"10.1016\/0277-9536(91)90149-7"},{"key":"2020021223564657700_REF18","doi-asserted-by":"crossref","unstructured":"Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21: 1352-1358.","DOI":"10.1200\/JCO.2003.05.108"},{"key":"2020021223564657700_REF19","doi-asserted-by":"crossref","unstructured":"Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19: 464-471.","DOI":"10.1200\/JCO.2001.19.2.464"},{"key":"2020021223564657700_REF20","doi-asserted-by":"crossref","unstructured":"O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348: 994-1004.","DOI":"10.1056\/NEJMoa022457"},{"key":"2020021223564657700_REF21","doi-asserted-by":"crossref","unstructured":"Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99: 1928-1937.","DOI":"10.1182\/blood.V99.6.1928"},{"key":"2020021223564657700_REF22","doi-asserted-by":"crossref","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344: 1031-1037.","DOI":"10.1056\/NEJM200104053441401"},{"key":"2020021223564657700_REF23","doi-asserted-by":"crossref","unstructured":"Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines. Blood. 2000;95: 3498-3505.","DOI":"10.1182\/blood.V95.11.3498"},{"key":"2020021223564657700_REF24","doi-asserted-by":"crossref","unstructured":"Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293: 876-880.","DOI":"10.1126\/science.1062538"},{"key":"2020021223564657700_REF25","doi-asserted-by":"crossref","unstructured":"Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96: 1070-1079.","DOI":"10.1182\/blood.V96.3.1070"},{"key":"2020021223564657700_REF26","doi-asserted-by":"crossref","unstructured":"le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000;95: 1758-1766.","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/6\/1898\/1701774\/zh801804001898.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/6\/1898\/1701774\/zh801804001898.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T23:57:00Z","timestamp":1581551820000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/6\/1898\/18877\/Late-effects-in-survivors-of-chronic-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,15]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,9,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-03-1010","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,15]]}}}